Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 33 Records) |
| Query Trace: Multiple Myeloma and TP53[original query] |
|---|
| Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma. Oncotarget 2014 Oct 5 (20): 9798-810. Kristensen Lasse Sommer, Asmar Fazila, Dimopoulos Konstantinos, Nygaard Mette Kathrine, Aslan Derya, Hansen Jakob Werner, Ralfkiaer Elisabeth, Grønbæk Kirst |
| Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell support. Leukemia & lymphoma 2015 Sep 1-11. Gebauer Niklas, Biersack Harald, Czerwinska Ann-Cathrin, Schemme Janina, Hardel Tim Tristan, Bernard Veronica, Rades Dirk, Lehnert Hendrik, Luley Kim Barbara, Thorns Christo |
| The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget 2017 Feb . Stein Caleb K, Pawlyn Charlotte, Chavan Shweta, Rasche Leo, Weinhold Niels, Corken Adam, Buros Amy, Sonneveld Pieter, Jackson Graham H, Landgren Ola, Mughal Tariq, He Jie, Barlogie Bart, Leif Bergsagel P, Davies Faith E, Walker Brian A, Morgan Gareth |
| Mutational landscape reflects the biological continuum of plasma cell dyscrasias. Blood cancer journal 2017 Feb 7 (2): e537. Rossi A, Voigtlaender M, Janjetovic S, Thiele B, Alawi M, März M, Brandt A, Hansen T, Radloff J, Schön G, Hegenbart U, Schönland S, Langer C, Bokemeyer C, Binder |
| Comprehensive molecular profiling of 718 Multiple Myelomas reveals significant differences in mutation frequencies between African and European descent cases. PLoS genetics 2017 Nov 13 (11): e1007087. Manojlovic Zarko, Christofferson Austin, Liang Winnie S, Aldrich Jessica, Washington Megan, Wong Shukmei, Rohrer Daniel, Jewell Scott, Kittles Rick A, Derome Mary, Auclair Daniel, Craig David Wesley, Keats Jonathan, Carpten John |
| A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood cancer journal 2018 3 8 (3): 35. White Brian S, Lanc Irena, O'Neal Julie, Gupta Harshath, Fulton Robert S, Schmidt Heather, Fronick Catrina, Belter Edward A, Fiala Mark, King Justin, Ahmann Greg J, DeRome Mary, Mardis Elaine R, Vij Ravi, DiPersio John F, Levy Joan, Auclair Daniel, Tomasson Michael |
| Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood 2018 10 132 (23): 2465-2469. Shah Vallari, Johnson David C, Sherborne Amy L, Ellis Sidra, Aldridge Frances M, Howard-Reeves Julie, Begum Farzana, Price Amy, Kendall Jack, Chiecchio Laura, Savola Suvi, Jenner Matthew W, Drayson Mark T, Owen Roger G, Gregory Walter M, Morgan Gareth J, Davies Faith E, Houlston Richard S, Cook Gordon, Cairns David A, Jackson Graham, Kaiser Martin F, |
| Chromothripsis 18 in multiple myeloma patient with rapid extramedullary relapse. Molecular cytogenetics 2018 11 7. Smetana Jan, Oppelt Jan, Štork Martin, Pour Lud?k, Kuglík Pe |
| EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. Clinical lymphoma, myeloma & leukemia 2019 Aug . Goldsmith Scott R, Fiala Mark A, O'Neal Julie, Souroullas George P, Toama Wael, Vij Ravi, Schroeder Mark |
| Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53. Oncotarget 2019 Jan 10 (7): 732-737. Ashby Cody, Tytarenko Ruslana G, Wang Yan, Weinhold Niels, Johnson Sarah K, Bauer Michael, Wardell Christopher P, Schinke Carolina, Thanendrarajan Sharmilan, Zangari Mauricio, van Rhee Frits, Davies Faith E, Sawyer Jeffrey R, Morgan Gareth J, Walker Brian |
| High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma. Blood 2019 Jan . Thakurta Anjan, Ortiz Maria, Blecua Pedro, Towfic Fadi, Corre Jill, Serbina Natalya V, Flynt Erin, Yu Zhinuan, Yang Zhihong, Palumbo Antonio, Dimopoulos Meletios A, Gutierrez Norma C, Goldschmidt Hartmut, Sonneveld Pieter, Avet-Loiseau Her |
| Genetic and transcriptional landscape of plasma cells in POEMS syndrome. Leukemia 2019 Jan . Nagao Yuhei, Mimura Naoya, Takeda June, Yoshida Kenichi, Shiozawa Yusuke, Oshima Motohiko, Aoyama Kazumasa, Saraya Atsunori, Koide Shuhei, Rizq Ola, Hasegawa Yoshinori, Shiraishi Yuichi, Chiba Kenichi, Tanaka Hiroko, Nishijima Dai, Isshiki Yusuke, Kayamori Kensuke, Kawajiri-Manako Chika, Oshima-Hasegawa Nagisa, Tsukamoto Shokichi, Mitsukawa Shio, Takeda Yusuke, Ohwada Chikako, Takeuchi Masahiro, Iseki Tohru, Misawa Sonoko, Miyano Satoru, Ohara Osamu, Yokote Koutaro, Sakaida Emiko, Kuwabara Satoshi, Sanada Masashi, Iwama Atsushi, Ogawa Seishi, Nakaseko Chia |
| The clonal evolution during long-term clinical course of multiple myeloma. International journal of hematology 2020 Aug . Mishima Yuko, Mishima Yuji, Shirouchi Yuko, Nishimura Noriko, Yokoyama Masahiro, Okabe Takashi, Inoue Norihito, Uryu Hideki, Fukuta Takanori, Hatake Kiyohiko, Terui Yasuhi |
| Early Relapse Risk in Patients with Newly Diagnosed Multiple Myeloma Characterized by Next-generation Sequencing. Clinical cancer research : an official journal of the American Association for Cancer Research 2020 7 26 (18): 4832-4841. D'Agostino Mattia, Zaccaria Gian Maria, Ziccheddu Bachisio, Rustad Even H, Genuardi Elisa, Capra Andrea, Oliva Stefania, Auclair Daniel, Yesil Jennifer, Colucci Paola, Keats Jonathan J, Gambella Manuela, Bringhen Sara, Larocca Alessandra, Boccadoro Mario, Bolli Niccolò, Maura Francesco, Gay Frances |
| Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature communications 2020 6 11 (1): 2996. Mouhieddine Tarek H, Sperling Adam S, Redd Robert, Park Jihye, Leventhal Matthew, Gibson Christopher J, Manier Salomon, Nassar Amin H, Capelletti Marzia, Huynh Daisy, Bustoros Mark, Sklavenitis-Pistofidis Romanos, Tahri Sabrin, Hornburg Kalvis, Dumke Henry, Itani Muhieddine M, Boehner Cody J, Liu Chia-Jen, AlDubayan Saud H, Reardon Brendan, Van Allen Eliezer M, Keats Jonathan J, Stewart Chip, Mehr Shaadi, Auclair Daniel, Schlossman Robert L, Munshi Nikhil C, Anderson Kenneth C, Steensma David P, Laubach Jacob P, Richardson Paul G, Ritz Jerome, Ebert Benjamin L, Soiffer Robert J, Trippa Lorenzo, Getz Gad, Neuberg Donna S, Ghobrial Irene |
| Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 5 38 (21): 2380-2389. Bustoros Mark, Sklavenitis-Pistofidis Romanos, Park Jihye, Redd Robert, Zhitomirsky Benny, Dunford Andrew J, Salem Karma, Tai Yu-Tzu, Anand Shankara, Mouhieddine Tarek H, Chavda Selina J, Boehner Cody, Elagina Liudmila, Neuse Carl Jannes, Cha Justin, Rahmat Mahshid, Taylor-Weiner Amaro, Van Allen Eliezer, Kumar Shaji, Kastritis Efstathis, Leshchiner Ignaty, Morgan Elizabeth A, Laubach Jacob, Casneuf Tineke, Richardson Paul, Munshi Nikhil C, Anderson Kenneth C, Trippa Lorenzo, Aguet François, Stewart Chip, Dimopoulos Meletios-Athanasios, Yong Kwee, Bergsagel P Leif, Manier Salomon, Getz Gad, Ghobrial Irene |
| del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. Blood 2020 10 137 (9): 1192-1195. Corre Jill, Perrot Aurore, Caillot Denis, Belhadj Karim, Hulin Cyrille, Leleu Xavier, Mohty Mohamad, Facon Thierry, Buisson Laure, Do Souto Laura, Lannes Romain, Dufrechou Stephanie, Prade Naïs, Orsini-Piocelle Frederique, Voillat Laurent, Jaccard Arnaud, Karlin Lionel, Macro Margaret, Brechignac Sabine, Dib Mamoun, Sanhes Laurence, Fontan Jean, Clement-Filliatre Lauriane, Marolleau Jean-Pierre, Minvielle Stephane, Moreau Philippe, Avet-Loiseau Her |
| Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma. Turkish journal of haematology : official journal of Turkish Society of Haematology 2021 5 38 (4): 246-253. Ye Fang, Wang Tongtong, Liu Aijun, Li Yanchen, Li Ningning, Wang Huan, Chen Wenmi |
| Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma. Leukemia & lymphoma 2021 10 63 (2): 385-394. Lee Youngeun, Yun Jiwon, Jeong Dajeong, Ryu Sohee, Kwon Seok Ryun, Yun Hongseok, Kim Sung Min, Park Jae Hyeon, Lee Dong So |
| Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma. Clinical epigenetics 2022 7 14 (1): 93. Zhang Lina, Zhang Run, Wang Jing, Chen Ying, Qiao Chun, Shi Qinglin, Jin Yuanyuan, Shen Xuxing, Li Jianyong, Chen Liju |
| Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence. Leukemia 2022 6 36 (7): 1887-1897. Misund Kristine, Hofste Op Bruinink Davine, Coward Eivind, Hoogenboezem Remco M, Rustad Even Holth, Sanders Mathijs A, Rye Morten, Sponaas Anne-Marit, van der Holt Bronno, Zweegman Sonja, Hovig Eivind, Meza-Zepeda Leonardo A, Sundan Anders, Myklebost Ola, Sonneveld Pieter, Waage Ande |
| Prognostic role of TNF alpha, LT alpha, MDR1 and codon 72 Tp53 gene polymorphisms on multiple myeloma Egyptian patients. Leukemia research 2022 Jun 117 106854. Hegazi Heba M, Elghonemy M S, El-Baiomy M A, Soliman Eman A, Abdel-Hady Elsayed |
| Genomic characterization of functional high-risk multiple myeloma patients. Blood cancer journal 2022 2 12 (1): 24. Soekojo Cinnie Yentia, Chung Tae-Hoon, Furqan Muhammad Shaheryar, Chng Wee J |
| Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood advances 2022 10 7 (2): 236-245. Barnell Erica K, Skidmore Zachary L, Newcomer Kenneth F, Chavez Monique, Campbell Katie M, Cotto Kelsy C, Spies Nicholas C, Ruzinova Marianna B, Wang Tianjiao, Abro Brooj, Kreisel Friederike, Parikh Bijal A, Duncavage Eric J, Frater John L, Lee Yi-Shan, Hassan Anjum, King Justin A, Kohnen Daniel R, Fiala Mark A, Welch John S, Uy Geoffrey L, Vij Kiran, Vij Ravi, Griffith Malachi, Griffith Obi L, Wartman Lukas |
| Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma. Blood 2022 10 141 (6): 620-633. Ansari-Pour Naser, Samur Mehmet, Flynt Erin, Gooding Sarah, Towfic Fadi, Stong Nicholas, Estevez Maria Ortiz, Mavrommatis Konstantinos, Walker Brian, Morgan Gareth, Munshi Nikhil, Avet-Loiseau Herve, Thakurta Anj |
| Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood cancer journal 2022 01 12 (1): 15. Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Vigliotta I, Rizzello I, Rocchi S, Armuzzi S, Testoni N, Marzocchi G, Martinelli G, Cavo M, Terragna |
| Association of Chromosome 17 Aneuploidy, TP53 Deletion, Expression and Its rs1042522 Variant with Multiple Myeloma Risk and Response to Thalidomide/Bortezomib Treatment. Cancers 2023 10 15 (19): . Sylwia Popek-Marciniec, Wojciech Styk, Magdalena Wojcierowska-Litwin, Sylwia Chocholska, Aneta Szudy-Szczyrek, Marzena Samardakiewicz, Grazyna Swiderska-Kolacz, Joanna Czerwik-Marcinkowska, Szymon Zmorzyns |
| Somatic mutation phasing and haplotype extension using linked-reads in multiple myeloma. bioRxiv : the preprint server for biology 2024 8 . Steven M Foltz, Yize Li, Lijun Yao, Nadezhda V Terekhanova, Amila Weerasinghe, Qingsong Gao, Guanlan Dong, Moses Schindler, Song Cao, Hua Sun, Reyka G Jayasinghe, Robert S Fulton, Catrina C Fronick, Justin King, Daniel R Kohnen, Mark A Fiala, Ken Chen, John F DiPersio, Ravi Vij, Li Di |
| The role of clonal progression leading to the development of therapy-related myeloid neoplasms. Annals of hematology 2024 7 . Luca Guarnera, Maria Rosaria Pascale, Hajro Hajrullaj, Antonio Cristiano, Flavia Mallegni, Angelo Onorato, Maria Teresa Voso, Emiliano Fabia |
| The significance of RB1 in multiple myeloma. Frontiers in immunology 2024 12 15 1415972. Yiwen Wang, Rui Yang, Rui Liu, Ruoyu Yang, Zujie Lin, Aili |
- Page last reviewed:Feb 1, 2024
- Content source: